Felipe Bedoya, Ph.D.

Felipe Bedoya, Ph.D., is the Director of Cell Biology at Kite Pharma, a biotechnology company focused on developing innovative cancer therapies, particularly in the area of CAR T cell therapy. He has a robust background in research and development, specializing in both autologous and allogeneic CAR T cell therapies.

Education and Career

• Education: Dr. Bedoya completed his Ph.D. at the University of Pennsylvania School of Medicine, where he focused on significant advancements in cell biology and immunotherapy.
• Current Role: At Kite Pharma, Dr. Bedoya leads efforts in research and development (R&D), process development, and chemistry, manufacturing, and controls (CMC) related to CAR T cell therapies. His work involves optimizing these therapies to enhance their efficacy and safety for patients.

Research Contributions

Dr. Bedoya's research interests include:

• Development of universal/allogeneic CAR T cells, which aim to provide off-the-shelf solutions for cancer treatment.
• Addressing challenges associated with traditional autologous CAR T cell therapies, such as production time and patient-specific limitations.

His contributions to the field are reflected in various publications and presentations that discuss advancements in CAR T cell technology and its applications in treating different types of cancers.

For more detailed insights into his professional background, you can view his LinkedIn profile here .1